OpenURL Connection Search

Select item for more details and to access through your institution.

Letter: irritable bowel syndrome—how a low‐FODMAP diet or yoga might help. Authors’ reply.
Published in:
2018
By:
- Schumann, D.;
- Cramer, H.
Publication type:
Letter to the Editor
Editorial: irritable bowel syndrome—in addition to having properly‐trained dietitians, is it time to add a yoga teacher to our multidisciplinary team? Authors’ reply.
Published in:
2018
By:
- Schumann, D.;
- Cramer, H.
Publication type:
Editorial
Editorial: NAFLD‐related hepatocellular carcinoma ‐ increasing or not? With or without cirrhosis?
Published in:
2018
By:
- Balakrishnan, M.;
- El‐Serag, H. B.
Publication type:
Editorial
Editorial: the role of colonic inflammation in the progression of liver disease in primary sclerosing cholangitis—Authors’ reply and Letter: the effects of colectomy prior to the diagnosis of primary sclerosing cholangitis on prognosis may have been overestimated
Published in:
2018
By:
- Nordenvall, C.;
- Bergquist, A.
Publication type:
Editorial
Letter: proton pump inhibitor use and fracture risk.
Published in:
2018
By:
- Sugiyama, T.
Publication type:
Letter to the Editor
Editorial: early post‐induction anti‐TNF drug monitoring can predict long‐term therapeutic outcomes in inflammatory bowel disease.
Published in:
2018
By:
- Papamichael, K.;
- Cheifetz, A. S.
Publication type:
Editorial
Letter: the safety of herpes zoster vaccination for patients with inflammatory bowel disease being treated with anti‐TNF medications—authors’ reply.
Published in:
2018
By:
- Khan, N.;
- Lewis, J. D.
Publication type:
Letter to the Editor
Editorial: mitigating primary nonresponse to infliximab—are we better equipped now?
Published in:
2018
By:
- Sawbridge, D.;
- Subramanian, S.
Publication type:
Editorial
Letter: therapeutic drug monitoring and inflammatory bowel disease—a call for an urgent standardization of the results.
Published in:
2018
By:
- Ribaldone, D. G.;
- Saracco, G. M.;
- Astegiano, M.;
- Pellicano, R.
Publication type:
Letter to the Editor
Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12‐month multicentre observational prospective cohort study.
Published in:
Alimentary Pharmacology & Therapeutics, 2018, v. 47, n. 3, p. 356, doi. 10.1111/apt.14453
By:
- Broeren, M. A. C.;
- Schmitz, E. M. H.;
- Scharnhorst, V.;
- Brunsveld, L.;
- Boekema, P. J.;
- Straathof, J. W. A.;
- van Renswouw, D. C.;
- van de Poll, M. E. C.;
- Derijks, L. J. J.
Publication type:
Article
Anti‐infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical response.
Published in:
Alimentary Pharmacology & Therapeutics, 2018, v. 47, n. 3, p. 346, doi. 10.1111/apt.14452
By:
- Dreesen, E.;
- Van Stappen, T.;
- Peeters, M.;
- Compernolle, G.;
- Tops, S.;
- Gils, A.;
- Ballet, V.;
- Van Assche, G.;
- Ferrante, M.;
- Vermeire, S.;
- Van Steen, K.
Publication type:
Article
Systematic review: human gut dysbiosis induced by non‐antibiotic prescription medications.
Published in:
Alimentary Pharmacology & Therapeutics, 2018, v. 47, n. 3, p. 332, doi. 10.1111/apt.14451
By:
- Le Bastard, Q.;
- Grégoire, M.;
- Chapelet, G.;
- Javaudin, F.;
- Dailly, E.;
- Batard, E.;
- Montassier, E.;
- Al‐Ghalith, G. A.;
- Knights, D.
Publication type:
Article
The long‐term effects of faecal microbiota transplantation for gastrointestinal symptoms and general health in patients with recurrent <italic>Clostridium difficile</italic> infection.
Published in:
Alimentary Pharmacology & Therapeutics, 2018, v. 47, n. 3, p. 371, doi. 10.1111/apt.14443
By:
- Jalanka, J.;
- Satokari, R.;
- Hillamaa, A.;
- Mattila, E.;
- Anttila, V.‐J.;
- Arkkila, P.
Publication type:
Article
Editorial: irritable bowel syndrome—in addition to having properly‐trained dietitians, is it time to add a yoga teacher to our multidisciplinary team?
Published in:
2018
By:
- Muir, J. G.;
- Iacovou, M.
Publication type:
Editorial
Editorial: critical care cholangiopathy—rare but important.
Published in:
2018
By:
- MacGilchrist, A.
Publication type:
Editorial
Letter: the effects of colectomy prior to the diagnosis of primary sclerosing cholangitis on prognosis may have been overestimated.
Published in:
2018
By:
- Tao, P.;
- Wang, S. Y.
Publication type:
Letter to the Editor
Regional gastrointestinal contractility parameters using the wireless motility capsule: inter‐observer reproducibility and influence of age, gender and study country.
Published in:
Alimentary Pharmacology & Therapeutics, 2018, v. 47, n. 3, p. 391, doi. 10.1111/apt.14438
By:
- Drewes, A. M.;
- Brock, C.;
- Farmer, A. D.;
- Wegeberg, A.‐M. L.;
- Mohammed, S. D.;
- Scott, S. M.;
- Bruckner‐Holt, C. E.;
- Brock, B.;
- Hobson, A. R.;
- Semler, J. R.;
- Hasler, W. L.;
- Hellström, P. M.
Publication type:
Article
Systematic review with meta‐analysis: thiopurines decrease the risk of colorectal neoplasia in patients with inflammatory bowel disease.
Published in:
Alimentary Pharmacology & Therapeutics, 2018, v. 47, n. 3, p. 318, doi. 10.1111/apt.14436
By:
- Lu, M. J.;
- Qiu, X. Y.;
- Mao, X. Q.;
- Li, X. T.;
- Zhang, H. J.
Publication type:
Article
Letter: the safety of herpes zoster vaccination for patients with inflammatory bowel disease being treated with anti‐TNF medications.
Published in:
2018
By:
- Côté‐Daigneault, J.;
- Luong, M. L.;
- Colombel, J.‐F.;
- Peerani, F.
Publication type:
Letter to the Editor
Letter: irritable bowel syndrome—how a low‐FODMAP diet or yoga might help.
Published in:
2018
By:
- Uno, Y.
Publication type:
Letter to the Editor
Market share and costs of biologic therapies for inflammatory bowel disease in the USA.
Published in:
Alimentary Pharmacology & Therapeutics, 2018, v. 47, n. 3, p. 364, doi. 10.1111/apt.14430
By:
- Yu, H.;
- Sellers, Z. M.;
- Wren, A. A.;
- Bensen, R.;
- Park, K. T.;
- MacIsaac, D.;
- Kin, C.;
- Wong, J. J.
Publication type:
Article
Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real‐world results from 18 378 patients in Egypt.
Published in:
Alimentary Pharmacology & Therapeutics, 2018, v. 47, n. 3, p. 421, doi. 10.1111/apt.14428
By:
- Omar, H.;
- El Akel, W.;
- Elbaz, T.;
- Said, M.;
- Doss, W.;
- Esmat, G.;
- Ismail, S. A.;
- El Kassas, M.;
- Elsaeed, K.;
- Shaker, M. K.;
- El Shazly, Y.;
- El Shazly, H.;
- Waked, I.;
- Yousif, M.;
- Gomaa, A. A.;
- Nasr, A.;
- AbdAllah, M.;
- Korany, M.
Publication type:
Article
Hepatitis B reactivation and outcomes in persons treated with directly acting antiviral agents against hepatitis C virus: results from ERCHIVES.
Published in:
Alimentary Pharmacology & Therapeutics, 2018, v. 47, n. 3, p. 412, doi. 10.1111/apt.14426
By:
- Yan, P.;
- Butt, A. A.;
- Shaikh, O. S.;
- Abou‐Samra, A.‐B.
Publication type:
Article
Reversibility of atrophic gastritis and intestinal metaplasia after <italic>Helicobacter pylori</italic> eradication ‐ a prospective study for up to 10 years.
Published in:
Alimentary Pharmacology & Therapeutics, 2018, v. 47, n. 3, p. 380, doi. 10.1111/apt.14424
By:
- Hwang, Y.‐J.;
- Choi, Y. J.;
- Yoon, H.;
- Shin, C. M.;
- Park, Y. S.;
- Kim, N.;
- Lee, D. H.;
- Lee, H. S.;
- Lee, J. B.
Publication type:
Article
Editorial: the role of colonic inflammation in the progression of liver disease in patients with primary sclerosing cholangitis.
Published in:
2018
By:
- Sabino, J.;
- Torres, J.
Publication type:
Editorial
Sofosbuvir and daclatasvir therapy in patients with hepatitis C‐related advanced decompensated liver disease (MELD ≥ 15).
Published in:
Alimentary Pharmacology & Therapeutics, 2018, v. 47, n. 3, p. 401, doi. 10.1111/apt.14404
By:
- the Australian Liver Association Clinical Research Network;
- McCaughan, G. W.;
- Strasser, S. I.;
- Mason, S.;
- Thwaites, P. A.;
- Morales, B.;
- Gow, P.;
- Parker, F. C.;
- Angus, P. W.;
- Roberts, S. K.;
- Mitchell, J.;
- Wigg, A.;
- Tallis, C.;
- Jeffrey, G.;
- George, J.;
- Thompson, A. J.
Publication type:
Article
Issue Information.
Published in:
Alimentary Pharmacology & Therapeutics, 2018, v. 47, n. 3, p. 315, doi. 10.1111/apt.14297
Publication type:
Article

Found: 27